Keywords: zevalin, aggressive, lymphoma, trial, german, drugmaker, schering

Zevalin in aggressive Lymphoma trial

Article | 16 October 2006

Print This

German drugmaker Schering AG and US biotechnology firm Biogen Idec say that they have begun a Phase III trial of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in